BackgroundThe Constant Load Treadmill Test (CLTT) is currently the primary method used to measure walking impairment in patients with peripheral vascular disease. The aim of this study was to compare the CLTT and PADHOC device as assessments of walking impairment.Methods55 patients with intermittent claudication underwent a CLTT and a Double Physiological Walking Test (DPWT) using the PADHOC device. Health-related quality of life was measured using the Short Form 36 and the Claudication Scale.ResultsThe initial claudication and maximum walking distance from the first part of the DPWT showed the best correlation with domains of pain and physical function.ConclusionsThe DPWT is more representative of the functional incapacity experienced by p...
Objectives:To compare a new pedal ergometer (the Stresst'er) with conventional treadmill examination...
ObjectiveThe aim of this study was to examine whether the plantar flexion test could adequately repl...
Peripheral artery disease affects over 236 million people globally and the classic symptom is interm...
BackgroundThe Constant Load Treadmill Test (CLTT) is currently the primary method used to measure wa...
AbstractObjectives: to assess a new method of determining functional impairment in patients with int...
Objectives:To compare the correlation and practicability of single-stage vs. graded treadmill protoc...
ObjectiveAssessment of walking distance by treadmill testing is the most commonly used method to eva...
Purpose: To compare treadmill and shuttle walk tests for assessing functional capacity in patients w...
AbstractBackground: Most trials on the reliability of constant-load treadmill testing use one pair o...
ObjectiveWe used outdoor walking distance measured during 40 minutes as “real-life” outdoor walking ...
ObjectiveIn patients with peripheral artery disease (PAD), the different distances between stops and...
A systematic review was conducted to identify the range of terminology used in studies to describe m...
Objective. To evaluate a new treadmill test, determining pain threshold speed (PTS) for use in asses...
Peripheral arterial disease (PAD) is defined by atherosclerotic plaque buildup and subsequent blocka...
AbstractObjective. To evaluate a new treadmill test, determining pain threshold speed (PTS) for use ...
Objectives:To compare a new pedal ergometer (the Stresst'er) with conventional treadmill examination...
ObjectiveThe aim of this study was to examine whether the plantar flexion test could adequately repl...
Peripheral artery disease affects over 236 million people globally and the classic symptom is interm...
BackgroundThe Constant Load Treadmill Test (CLTT) is currently the primary method used to measure wa...
AbstractObjectives: to assess a new method of determining functional impairment in patients with int...
Objectives:To compare the correlation and practicability of single-stage vs. graded treadmill protoc...
ObjectiveAssessment of walking distance by treadmill testing is the most commonly used method to eva...
Purpose: To compare treadmill and shuttle walk tests for assessing functional capacity in patients w...
AbstractBackground: Most trials on the reliability of constant-load treadmill testing use one pair o...
ObjectiveWe used outdoor walking distance measured during 40 minutes as “real-life” outdoor walking ...
ObjectiveIn patients with peripheral artery disease (PAD), the different distances between stops and...
A systematic review was conducted to identify the range of terminology used in studies to describe m...
Objective. To evaluate a new treadmill test, determining pain threshold speed (PTS) for use in asses...
Peripheral arterial disease (PAD) is defined by atherosclerotic plaque buildup and subsequent blocka...
AbstractObjective. To evaluate a new treadmill test, determining pain threshold speed (PTS) for use ...
Objectives:To compare a new pedal ergometer (the Stresst'er) with conventional treadmill examination...
ObjectiveThe aim of this study was to examine whether the plantar flexion test could adequately repl...
Peripheral artery disease affects over 236 million people globally and the classic symptom is interm...